Erste Asset Management GmbH Boosts Stake in Boston Scientific Corporation $BSX

Key Points

• Erste Asset Management GmbH increased its holdings in Boston Scientific by 19.9%, now owning 287,610 shares valued at approximately $28.88 million.
• The company reported $5.06 billion in quarterly revenue, surpassing estimates, and set its Q3 2025 guidance at $0.700-$0.720 EPS.
• Insider transactions included CEO Michael F. Mahoney selling over 164,000 shares, representing a 10.02% decrease in his position.

Erste Asset Management GmbH boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 19.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 287,610 shares of the medical equipment provider's stock after acquiring an additional 47,756 shares during the quarter. Erste Asset Management GmbH's holdings in Boston Scientific were worth $28,879,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Colonial Trust Co SC increased its stake in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares during the last quarter. Investment Management Corp VA ADV acquired a new stake in Boston Scientific during the fourth quarter worth $25,000. Sunbeam Capital Management LLC acquired a new stake in Boston Scientific during the fourth quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific during the first quarter worth $27,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BSX. Leerink Partners began coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective for the company. Robert W. Baird lifted their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. UBS Group lifted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Morgan Stanley lifted their price objective on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Finally, Truist Financial lifted their price objective on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Stock Up 0.7%

BSX traded up $0.7850 on Friday, hitting $105.9950. 9,396,775 shares of the company were exchanged, compared to its average volume of 6,145,860. Boston Scientific Corporation has a twelve month low of $78.53 and a twelve month high of $108.94. The company has a market cap of $157.06 billion, a price-to-earnings ratio of 63.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.66. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $104.10 and a two-hundred day moving average price of $102.14.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. The trade was a 58.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 over the last three months. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.